---
id: 075
title: HIV Antiretroviral Therapy Classes
category: antimicrobials
subcategory: antivirals_hiv
tags: [HIV, ART, INSTI, NNRTI, PI, NRTI, integrase-inhibitors]
difficulty: medium
---

## Question

What are the major HIV ART drug classes? Use the **"IN-NNRTI-PI-NRTI"** mnemonic.

## Answer

### **"IN-NNRTI-PI-NRTI" Mnemonic:**

**IN (Integrase Strand Transfer Inhibitors - PREFERRED):**
- **I**ntegrase enzyme target (newest, best tolerated)
- **N**ow first-line (dolutegravir, bictegravir)

**NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors):**
- **N**on-competitive RT inhibition
- **N**evirapine, efavirenz (older)
- **R**ash, hepatotoxicity common
- **T**eratogenic (efavirenz)
- **I**nduces/inhibits CYP450

**PI (Protease Inhibitors):**
- **P**rotease enzyme blocks virion maturation
- **I**nhibit CYP3A4 (drug interactions)

**NRTI (Nucleoside RTIs - Backbone):**
- **N**ucle oside analogs
- **R**everse transcriptase competitive inhibition
- **T**enofovir, emtricitabine (TAF/TDF + FTC)
- **I**ncorporated into viral DNA → chain termination

### **Drug Classes and Examples:**

| Class | Mechanism | Examples | Role |
|-------|-----------|----------|------|
| **INSTI** | Inhibits **integrase** | **Dolutegravir**, bictegravir, raltegravir | **1st-line** (anchor) |
| **NNRTI** | Non-competitive **RT** inhibitor | Efavirenz, rilpivirine | Alternative anchor |
| **PI** | Inhibits **protease** | Darunavir/r, atazanavir/r | Salvage/alternative |
| **NRTI** | Competitive **RT** inhibitor | **TAF/FTC**, **TDF/FTC**, ABC/3TC | **Backbone** (all regimens) |
| **Entry inhibitors** | Blocks CCR5/fusion | Maraviroc | Rarely used |

### **Modern First-Line Regimens (2024):**

**Preferred Regimens:**
1. **Bictegravir/TAF/FTC** (Biktarvy) - single tablet daily
2. **Dolutegravir + TAF/FTC** (or TDF/FTC)
3. **Dolutegravir/ABC/3TC** (Triumeq) - if HLA-B*5701 negative

**Structure:** **INSTI (anchor) + 2 NRTIs (backbone)**

## Key Points

### **Why INSTIs Are Preferred:**
- **Best tolerated** (fewest side effects)
- **High genetic barrier** to resistance
- **No food restrictions** (most)
- **Fewer drug interactions** than PIs/NNRTIs
- **Rapid viral suppression**

### **NRTI Backbone Choice:**

| Backbone | Advantages | Disadvantages |
|----------|------------|---------------|
| **TAF/FTC** | Less renal/bone toxicity than TDF | Weight gain, ↑ lipids |
| **TDF/FTC** | Well-studied, generic | Renal toxicity, ↓ bone density |
| **ABC/3TC** | No renal toxicity | HLA-B*5701 testing required (hypersensitivity) |

### **Class-Specific Toxicities:**

**NRTIs:**
- **TDF:** Renal toxicity (Fanconi syndrome), ↓ bone density
- **ABC:** Hypersensitivity reaction (if HLA-B*5701+)
- **All:** Lactic acidosis (rare, mitochondrial toxicity)

**INSTIs:**
- **Dolutegravir:** Weight gain, insomnia (rare neural tube defects if used periconception)
- **Raltegravir:** Generally well-tolerated
- **Bictegravir:** Weight gain

**NNRTIs:**
- **Efavirenz:** CNS effects (vivid dreams, dizziness), rash, teratogenic
- **Nevirapine:** Hepatotoxicity, Stevens-Johnson syndrome

**PIs:**
- **All:** GI intolerance, metabolic (↑ lipids, lipodystrophy, insulin resistance)
- **Darunavir:** Rash, sulfa allergy cross-reaction

### **Clinical Pearls:**
- **Single-tablet regimens** (STRs) improve adherence
- **INSTIs preferred** over PIs/NNRTIs (better tolerated)
- **3-drug regimen** standard (INSTI + 2 NRTIs)
- **Resistance testing** before starting ART
- **Goal:** Undetectable viral load (<20-50 copies/mL) within 3-6 months

## Sources

- [DHHS Guidelines: Adult/Adolescent ART 2024]
- [IAS-USA: Antiretroviral Drugs for Treatment]

## Media

N/A
